A study of 137 patients found edaravone use lead to less functional loss than placebo, contrasting with results from a previous Phase 3 study which found no efficacy of the treatment over placebo.
HBsAg decline at week 24 and baseline HBsAg levels are better predictors of functional cure than novel virologic markers, while on-treatment HBV RNA and HBeAg levels and dynamic changes are the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results